Insilico and Elevian enter a research collaboration to discover drugs that target aging

(InSilico Medicine, Inc.) Elevian, a biotech therapeutics company focused on reversing molecular damage caused by aging, and Insilico Medicine, an artificial intelligence (AI) company developing an end-to-end pipeline for automated target identification, small molecule generation, prediction of clinical trials outcomes and aging research, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.

from EurekAlert! - Social and Behavioral Science http://bit.ly/2QDMiRW